donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AZN AstraZeneca > Key Indicators
AZN AstraZeneca
66.130
-0.380-0.57%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
63.22% -236.5091 3.64% 162.9207 3.64% 162.9207 54.77% -271.6037
Receivable Turnover(T)
14.19% 5.5449 5.62% 7.6074 5.62% 7.6074 -0.29% 4.7129
Inventory Turnover(T)
52.5% 2.3667 30.23% 1.9124 30.23% 1.9124 -13.13% 1.3141
Fixed Assets Turnover(T)
34.27% 4.3985 27.05% 3.9205 27.05% 3.9205 12.09% 3.5435
Total Asset Rate(T)
11.2% 0.5023 4.64% 0.4348 4.64% 0.4348 -8.92% 0.3831
ROIC
-100.56% -0.088% -82.99% 2.095% -82.99% 2.095% -53.77% 4.936%
ROE
-113.27% -4.187% -98.16% 0.408% -98.16% 0.408% -72.37% 5.664%
ROA
-119.76% -1.287% -97.39% 0.130% -97.39% 0.130% -57.7% 1.717%
FCF to Sales
-11.8% 12.455% 22.06% 10.057% 22.06% 10.057% 75.9% 13.143%
FCF to Net Income
-- -- 4796.49% 3359.821% 4796.49% 3359.821% 278.75% 293.202%
Efficiency Ratios
ROE 5 Year Average
-- -- -22.99% 13.784% -- -- -- --
ROA 5 Year Average
-- -- -26.39% 3.110% -- -- -- --
Average 5 Years ROIC
-- -- -22.11% 8.801% -- -- -- --
Profitability Ratios TTM
Gross Margin
-16.58% 66.052% -16.64% 66.761% -16.64% 66.761% -10.66% 71.547%
Operating Margin
-117.52% -2.774% -102.58% -0.358% -102.58% -0.358% -67.43% 5.903%
Net Margin
-117.77% -2.562% -97.51% 0.299% -97.51% 0.299% -53.56% 4.483%
EBITDA Margin
-47.69% 0.1695% -35.66% 0.2015% -35.66% 0.2015% -24.64% 0.2415%
R & D Expense Ratio
3.29% 24.480% 11.48% 26.020% 11.48% 26.020% -5.09% 22.950%
Sales Expense Ratio
-3.87% 42.230% -6.8% 41.650% -6.8% 41.650% 5.75% 35.290%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-36.01% 79.265% -36.13% 73.566% -36.13% 73.566% -52.65% 72.814%
Total Assets to Common Equity
-38.67% 275.930% -37.18% 268.318% -37.18% 268.318% -48.68% 269.779%
Debt to Asset Ratio
-38.66% 85.578% -39.91% 78.387% -39.91% 78.387% -56.17% 80.294%
Current Ratio
14.36% 0.9959 20.69% 1.1615 20.69% 1.1615 17.68% 1.1286
Quick Ratio
-2.3% 0.6379 -1.65% 0.6431 -1.65% 0.6431 -12.57% 0.6515
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- 230.2% 19.204% -- -- -- --
Revenue CAGR(5Y)
-- -- 581.52% 10.220% -- -- -- --
Net Income CAGR(3Y)
-- -- -3055.7% -62.682% -- -- -- --
Net Income CAGR(5Y)
-- -- -2091.57% -49.759% -- -- -- --
Dividend CAGR(3Y)
-- -- -- 0.000% -- -- -- --
Dividend CAGR(5Y)
-- -- -- 0.000% -- -- -- --
FCF 1 Year Growth
-- -- -78.36% 71.591% -- -- -- --
FCF CAGR(3Y)
-- -- 1055.88% 44.507% -- -- -- --
FCF CAGR(5Y)
-- -- -52.39% 15.497% -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
CEO: Soriot M.B.A., Pascal
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...